Nanomilling achieves more targeted drug delivery

More than 90% of drugs approved since 1995 have poor solubility, poor permeability or both. Drug performance can be improved by reducing the particle size and at the same time increasing the specific surface area of the APIs. Therefore, however an API is administered — in tablet, capsule, powder or liquid form — small particle sizes offer exciting advantages for pharmaceuticals. Known benefits include improved dissolution rate, increased bioavailability and higher activity, leading to lower dosages and a lower risk of side effects for the patient.

The NETZSCH DELTAVITA mill has been specially designed to efficiently increase solubility of APIs, thereby enhancing their efficacy. DELTAVITA mills achieve excellent repeatability as well as homogeneous dispersion and produce a very narrow range of ultra fine particles in a homogeneous formulation.

With the DELTAVITA, users can achieve consistent particle size distributions below 100 µm. With nanometer-scale particles, gene and vaccine delivery becomes more targeted, as does the development of particles that cross the blood brain barrier. Nanoparticles can enhance the properties of time-release molecules and nano-receptors can be added to drug surfaces to release drugs exactly where needed.

As for different models, the DELTAVITA is designed with flexibility in mind with several available chamber sizes in stainless steel and ceramic construction. The laboratory series sizes range from 15 to 300 ml chamber volumes and the pilot series offers 600 ml chamber volume. In the production series, NETZSCH offers models from 2,000 to 60,000 ml.

NETZSCH-Feinmahltechnik GmbH, www.netzsch.com/deltavita.